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OUTPATIENT HLA-HAPLOIDENTICAL STEM CELL TRANSPLANTATION IN
CHILDREN USING A REDUCED-INTENSITY CONDITIONING REGIMEN
AND CD3-CD19 DEPLETION
Gonzalez-Llano, O., Rodrıguez-Romo, L.N., Mancıas-Guerra, M.C.,
Jaime-Perez, J.C., Garcıa-Rodrıguez, F., Gomez-Almaguer, D. Hospital
Universitario ‘‘Dr. Jose Eleuterio Gonzalez’’ de la Universidad Autonoma
de Nuevo Leon, Monterrey, Nuevo Leon, Mexico
Background: Haploidentical stem cell transplantation (Haplo-
HSCT) has been developed as an alternative transplant strategy for
children with hematological disorders without a HLA matched do-
nor. Reduced-intensity conditioning (RIC) regimens allow haplo-
HSCT with less toxicity and have been used in children with good
results. Haplo-HSCT with RIC has been also carried out an outpa-
tient setting, but such strategy has not been extensively explored in
children.
Methods:We analyzed the outcome of fifteen consecutive paediat-
ric patients with various hematological diseases who underwent
a Haplo-HSCT using a RIC regimen and CD3/CD19 depletion in
an outpatient setting at our institution from January, 2009 to July,
2010. Stem-cell source was peripheral blood of mismatched family
donors. A uniform preparative regimen consisting of fludarabine, cy-
clophosphamide, antithymocyte globulin and melphalan was used.
Results: The grafts contained a median of 10x106 (range, 6.7–
18x106) CD34+ cells, and 10.7x105 (range, 2-21x105) CD3+ T cells.
Engraftment of neutrophils and platelets was achieved at a median of
14 (11 - 60) days and 14 (11 - 54) days, respectively. Ten patients en-
grafted with full donor chimerism. The regimen was well tolerated
withmaximum acute toxicity being grade 2mucositis in two patients.
Four patients experienced aGVHD $ grade II, two responded to
prednisone and cyclosporine, the others have to additionally receive
alemtuzumab with good initial response. One patient developed lim-
ited cGVHD and another developed extensive cGVHD. Two pa-
tients died due to infections and transplant related mortality was
20%. Twelve of fifteen patients (80%) showed transient or sustained
engraftment, five of them (33%) are free of disease with complete
chimerism at a median follow up of 9 months.
Conclusions: Our results suggest that Haplo-HSCT can be a rea-
sonable therapeutic alternative for children who have no family do-
nor or cord blood units available and that is possible to carry it out on
an outpatient basis.Table 1. Post- transplant characteristics and current status for 15 p
Case
Day of
ANC > 500
Day of PLT
> 20000 Chimerism aGVHD
1 +20 +17 Complete Skin grade I
2 +13 +17 Complete Skin grade III
3 +14 +11 Complete Skin grade I
4 +22 +20 90% Skin grade I
5 +13 +54 86% Skin grade II
6 +60 +14 13% No
7 +14 +11 Complete No
8 +27 +15 No No
9 +32 +32 No No
10 +14 +11 Complete Skin grade I and
Intestine grade II
11 +11 +13 Complete Skin grade I and
Intestine grade III
12 +30 +14 No No
13 +14 +14 80% No
14 +34 +40 10% No
15 +14 +12 Complete Skin grade I406
HLA ANTIBODIES IN COMBINED RELATED HAPLOIDENTICAL-UNRE-
LATED UMBILICAL CORD STEM CELL TRANSPLANTS
Marino, S.R., Weidner, J., Ramahi, S., Du, Z., van Besien, K. University
of Chicago Medical Center, Chicago, IL
Combined related haploidentical-unrelated umbilical cord blood
stem cell transplants (RH-UUCB SCT) is a new approach for treat-
ment of patients with hematological malignancies who lack HLA
matched donors.. Although additional cells from the haploidentical
donor reduce complications associated with late engraftment in
UUCB SCT, patients with RH-UUCB SCT are challenged with
a higher degree of HLA disparities and potential complication asso-
ciated with them.
In order to evaluate the impact of donor-specific HLA antibodies
(DSA) on outcome of high risk RH-UUCB SCTs, we enrolled 30
patients with hematologic malignancies and one with Severe aplastic
anemia who were transplanted between January 2007 and December
2009. Patient sera on pre-transplant, days 0, 7, 14, 28, 75, 100, and
180 were tested for HLA antibodies using Luminex based solid-
phase assays.
Twenty nine patients had either pre-SCT and/or post-SCT
specimens for antibody testing. Nineteen of 29 had pre-SCT spec-
imens (13:19 had no HLA antibodies; 7:19 had HLA antibodies
and only 3 of them had DSA). Of those, one died 3 days post-
SCT and cannot be evaluated; the second patient had DSA against
UCB with mean fluorescence intensity (MFI) . 10,000. She en-
grafted promptly but engraftment analysis demonstrated only
haplo-donor engraftment. Patient three had DSA against the hap-
loidentical donor and the UCB (MFI. 1,500). This patient did not
engraft and died 50 days post-transplant. Two patients had non-
DSA HLA antibodies in pre- and post-SCT specimens. They
both engrafted promptly and over time developed durable cord en-
graftment. Among 21 evaluable patients without pre transplant
HLA antibodies, 15 engrafted with the cord, 4 failed to engraft
at all and 2 had durable haplo-engraftment without detectable
cord engraftment. Three developed HLA antibodies post trans-
plant, but these were not DSA.
In Conclusion 17% of patients had HLA antibodies pre-RH-
UUCB-SCT, but only 10% had DSA. One patient with both RH
and UUCB donor-specific HLA antibodies (MFI . 1,500) died of
graft failure. One patient with DSA (MFI . 10,000) against
UUCB engrafted the haplo-donor cells and survived 200 days.
Only 3 patients developed de novo HLA antibodies post-SCT, but
no DSA.
The risk of cord failure is higher in patients withDSA (2/2) than in
patients without DSA (6/21), (p 5 0.11, Fishers exact). Presence of
HLA antibodies and MFI should be determined pre-transplant and
these results should be used to guide donor selection.atients receiving a Haplo HSCT.
cGVHD Status/Time post-transplant
No Alive on remission/ 19 months
No Relapsed at 3 moths post-transplant/Died at 8
months post-transplant
No Alive-Remission/ 13 months
No Died due to Lymphoproliferative disease at 5 months.
Extensive Died with extensive GVHD/ 11 months
No Rejected graft at 3 months/Alive on remission/ 12 months
No Alive on remission/12months
No Graft failure/Died at 6 months post-transplant due
to graft failure-sepsis
No Graft failure/Died at 6 months post-transplant due to relapse.
No Died due to pneumonia at 3 months post-transplant
Limited Alive with limited GVHD/ 9 months
No Graft failure/Alive on remission/ 8 months
No Rejected graft at 3 months/Relapse at 6 months
No Graft failure/Alive on remission/ 6 months
No Alive on remission/ 6 months
